← Back to all trials
Not Yet Recruiting
NCT05684952
The Efficacy and Safety of a Chinese Herbal Medicine for Long COVID Associated Fatigue
Conditions: Long COVID
Sex: All
Ages: 18 Years – 65 Years
Phase: PHASE2
Enrollment: 152
Sponsor: Hong Kong Baptist University
Location: China
Summary
This is a randomized, double-blinded, placebo-controlled clinical trial to determine the efficacy and safety of a Chinese herbal medicine (Shenlingcao oral liquid) for treating long COVID associated fatigue.
Eligibility Criteria
Inclusion Criteria:18-65 years adultsFulfill the long COVID diagnostic criteria by Centers for Disease Control and Prevention (CDC)Chalder fatigue scale (0-11) not less than 4Exclusion Criteria:Have any medical history that may cause fatigue before COVID-19 infection, which include but not limited to cardiovascular diseases, chronic lung diseases, dyspnea, cognitive diseases, psychological diseases, chronic liver or renal diseases, cancer, etc.Must chronically taking medicines that may affect the study results.Severe obesity (BMI not less than 45)Alcoholism or drug abuseAllergy to Chinese medicinePregnancy, or plan to be pregnant, or lactating women
Source: ClinicalTrials.gov (NCT05684952). StuddyBuddy aggregates publicly available trial information.
